Partial efficacy was also recently reported for the M72/AS01 candidate tuberculosis (TB) vaccine, when administered to adults in TB-endemic regions who had been infected with TB’s etiologic agent Mycobacterium tuberculosis (Mtb), as determined by interferon [IFN]-γ release assay [12, 13]. The gene discussed is IFNG; the disease is tuberculosis.